850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies
Ruth Plummer(National Health Service), Nagy Habib(Hammersmith Hospital), Jeffrey Yachnin(Karolinska University Hospital), Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Bridget P. Keenan(University of California, San Francisco), C.E. Chee(National University Cancer Institute, Singapore), Anthony B. El-Khoueiry(USC Norris Comprehensive Cancer Center), Bristi Basu(University of Cambridge), Antonio D’Alessio(Hammersmith Hospital), Bríd M. Ryan(National Institutes of Health), Daneng Li(City Of Hope National Medical Center), John J. Rossi(City Of Hope National Medical Center), Alison Adderkin, Nina Raulf(CTI BioPharma (United Kingdom)), Claudia Angela Maria Fulgenzi(Università Campus Bio-Medico), Rose Hogson, Vikash Reebye(Imperial College London), Marcus Smith Noel(University of Rochester), Tim Meyer(The Royal Free Hospital), Mikael H. Sodergren(Imperial College London), Julia Vassiliadou, Sarah P. Blagden(Churchill Hospital), Natalie Cook(Manchester Academic Health Science Centre), Choon Ping Tan, Maria Diab(Emory University), JEFF EVANS(University of Glasgow), Debashis Sarker(King's College - North Carolina), Kai‐Wen Huang(National Taiwan University Hospital), Joanna P. Nicholls(Imperial College London), Ilian Tachkov, Robert Habib, David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Cited by 1
Related Papers
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.1k